We Offer Worldwide Shipping
Login Wishlist

Isorauhimbine

$1,120

  • Brand : BIOFRON

  • Catalogue Number : BN-O1576

  • Specification : 98%(HPLC)

  • CAS number : 483-09-0

  • Formula : C21H26N2O3

  • Molecular Weight : 354.5

  • PUBCHEM ID : 6452110

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BN-O1576

Analysis Method

HPLC,NMR,MS

Specification

98%(HPLC)

Storage

-20℃

Molecular Weight

354.5

Appearance

Powder

Botanical Source

This product is isolated and purified from the root of Rauvolfia serpentina

Structure Type

Alkaloids

Category

Standards;Natural Pytochemical;API

SMILES

COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O

Synonyms

3-Epiisoyohimbine/3-epi-a-Yohimbine/3-epi-α-Yohimbine/Yohimban-16-carboxylic acid, 17-hydroxy-, methyl ester, (3β,16β,17α,20α)-/Isorauhimbine/Methyl (3β,16β,17α,20α)-17-hydroxyyohimban-16-carboxylate

IUPAC Name

methyl (1R,15S,18S,19S,20S)-18-hydroxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate

Applications

Density

1.3±0.1 g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

282.2±30.1 °C

Boiling Point

543.0±50.0 °C at 760 mmHg

Melting Point

InChl

InChI=1S/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3/t12-,15+,17-,18+,19+/m1/s1

InChl Key

BLGXFZZNTVWLAY-RIEHRDFOSA-N

WGK Germany

RID/ADR

HS Code Reference

2933990000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:483-09-0) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

32204444

Abstract

We have previously identified serum miR-483-5p as a preoperative diagnosis and prognosis biomarker for adrenocortical cancer (ACC). Here, we aimed to determine whether circulating miR-483-5p levels measured 3 months post-operatively distinguished patients with good prognosis (no recurrence for at least 3 years; NR3yrs) from patients with poor prognosis (recurrence or death within 3 years after surgery; R < 3yrs). We conducted a single-center retrospective analysis using sera from 48 patients with ACC that were initially non-metastatic and treated by surgery. Sera sampled within 3 months after surgery were available in 26 patients. MiR-483-5p absolute circulating levels were measured using quantitative PCR. Thirteen patients showed a recurrence before 3 years (=R < 3yrs). Thirteen patients showed no recurrence within 3 years, including 11 patients with a follow-up longer than 3 years (=NR3yrs). Serum miR-483-5p levels were higher in R < 3yrs than in NR3yrs: 1,541,990 ± 428,377 copies/mL vs. 388,457 ± 62,169 copies/mL (p = 0.002). Receiver operating characteristic analysis showed that a value of 752,898 copies/mL distinguished R < 3yrs from NR3yrs with 61.5% sensitivity (CI 31.6-86.1) and 100% specificity (CI 71.5-100) with an area under the curve of 0.853. Patients with a value below this threshold had a significantly longer recurrence-free and overall survival. In multivariate analysis, miR-483-5p provided the single best prognostic value for recurrence-free survival (RFS) (hazard ratio (HR) for recurrence 5.98, p < 0.011) but not for overall survival. Our study suggests that serum miR-483-5p is a potent early post-operative biomarker for ACC prognosis that might be a better predictor of RFS than currently used markers.

KEYWORDS

adrenocortical carcinoma, biomarker, circulating microRNA, miR-483-5p, early prognosis, recurrence

Title

Early Postoperative Circulating miR-483-5p Is a Prognosis Marker for Adrenocortical Cancer

Author

Maurine Oreglia,1 Silviu Sbiera,2 Martin Fassnacht,2 Laurent Guyon,3 Josiane Denis,3 Justine Cristante,1,3 Olivier Chabre,1,3 and Nadia Cherradi3,*

Publish date

2020 Mar;

PMID

24874644

Abstract

MicroRNAs (miRNAs), which play a role in tumorigenesis, may also serve as diagnostic or prognostic biomarkers. However, studies on human miRNA profiles in plasma from nasopharyngeal carcinoma (NPC) patients are in their infancy. Here, we used microarrays to perform systematic profiling of human miRNAs in plasma from NPC patients. We subsequently used real-time quantitative polymerase chain reaction (Q-PCR) to validate miRNAs with aberrant expression that could serve as potential biomarkers. By comparing the plasma miRNA profiles of 31 NPC patients and 19 controls, 39 of 887 human miRNAs were found to be aberrantly expressed. Considering the fold change and P value, miR-548q and miR-483-5p were validated in 132 samples from 82 NPC patients and 50 controls. Moreover, high expression of miR-548q and miR-483-5p was further found in 3 NPC cell lines and clinical biopsy tissues from 54 NPC patients and 22 controls. Our results revealed that miR-548q and miR-483-5p are potential biomarkers of NPC. Combining the receiver operating characteristic (ROC) analyses of these 2 miRNAs, an area under the ROC curve (AUC) of 0.737 with 67.1% sensitivity and 68.0% specificity were obtained, showing the preliminary diagnostic value of plasma miRNAs. Moreover, most NPC patients with a poor outcome exhibited high expression (> median) of miR-548q (70.6%) and miR-483-5p (64.7%) in tissue samples, indicating their prognostic value. The high expression levels of miR-548q and miR-483-5p in plasma, cell lines, and clinical tissues of NPC patients indicate that their roles in NPC should be explored in the future.

KEYWORDS

Nasopharyngeal carcinoma (NPC), microRNA profiles, potential biomarkers

Title

Plasma microRNA profiling in nasopharyngeal carcinoma patients reveals miR-548q and miR-483-5p as potential biomarkers

Author

Xiao-Hui Zheng,* Cui Cui,* Hong-Lian Ruan, Wen-Qiong Xue, Shao-Dan Zhang, Ye-Zhu Hu, Xin-Xi Zhou, and Wei-Hua Jia

Publish date

2014 Jul;

PMID

31677278

Abstract

Purpose
The goal of the present work was to provide a large set of detector‐specific output correction factors for seven small volume ionization chambers on two linear accelerators in four megavoltage photon beams utilizing perpendicular and parallel orientation of ionization chambers in the beam for nominal field sizes ranging from 0.5 cm2 × 0.5 cm2 to 10 cm2 × 10 cm2. The present study is the second part of an extensive research conducted by our group.

Methods
Output correction factors kfclin,frefQclin,Qref were experimentally determined on two linacs, Elekta Versa HD and Varian TrueBeam for 6 and 10 MV beams with and without flattening filter for nine square fields ranging from 0.5 cm2 × 0.5 cm2 to 10 cm2 × 10 cm2, for seven mini and micro ionization chambers, IBA CC04, IBA Razor, PTW 31016 3D PinPoint, PTW 31021 3D Semiflex, PTW 31022 3D PinPoint, PTW 31023 PinPoint, and SI Exradin A16. An Exradin W1 plastic scintillator and EBT3 radiochromic films were used as the reference detectors.

Results
For all ionization chambers, values of output correction factors kfclin,frefQclin,Qref were lower for parallel orientation compared to those obtained in the perpendicular orientation. Five ionization chambers from our study set, IBA Razor, PTW 31016 3D PinPoint, PTW 31022 3D PinPoint, PTW 31023 PinPoint, and SI Exradin A16, fulfill the requirement recommended in the TRS‐483 Code of Practice, that is, 0.95<kfclin,frefQclin,Qref<1.05, down to the field size 0.8 cm2 × 0.8 cm2, when they are positioned in parallel orientation; two of the ionization chambers, IBA Razor and PTW 31023 PinPoint, satisfy this condition down to the field size of 0.5 cm2 × 0.5 cm2.

Conclusions
The present paper provides experimental results of detector‐specific output correction factors for seven small volume ionization chambers. Output correction factors were determined in 6 and 10 MV photon beams with and without flattening filter down to the square field size of 0.5 cm2 × 0.5 cm2 for two orientations of ionization chambers — perpendicular and parallel. Our main finding is that output correction factors are smaller if they are determined in a parallel orientation compared to those obtained in a perpendicular orientation for all ionization chambers regardless of the photon beam energy, filtration, or linear accelerator being used. Based on our findings, we recommend using ionization chambers in parallel orientation, to minimize corrections in the experimental determination of field output factors. Latter holds even for field sizes below 1.0 cm2 × 1.0 cm2, whenever necessary corrections remain within 5%, which was the case for several ionization chambers from our set.

TRS‐483 recommended perpendicular orientation of ionization chambers for the determination of field output factors. The present study presents results for both perpendicular and parallel orientation of ionization chambers. When validated by other researchers, the present results for parallel orientation can be considered as a complementary dataset to those given in TRS‐483.

KEYWORDS

ionization chamber, orientation, output correction factor, small field

Title

Output correction factors for small static fields in megavoltage photon beams for seven ionization chambers in two orientations — perpendicular and parallel

Author

Božidar Casar,corresponding author 1 Eduard Gershkevitsh, 2 Ignasi Mendez, 1 Slaven Jurković, 3 , 4 and M. Saiful Huq 5

Publish date

2020 Jan